CAXTON CORP 13D and 13G filings for Cardiff Oncology, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 12:47 pm Sale | 2022-12-31 | 13G | Cardiff Oncology, Inc. CRDF | CAXTON CORP | 983,607 2.200% | -2,495,733 (-71.73%) | Filing |
| 2022-02-14 4:13 pm Purchase | 2021-12-31 | 13G | Cardiff Oncology, Inc. CRDF | CAXTON CORP | 3,479,340 8.100% | 380,893 (+12.29%) | Filing |
| 2021-02-16 3:30 pm Purchase | 2021-12-31 | 13G | Cardiff Oncology, Inc. CRDF | CAXTON CORP | 3,098,447 8.800% | 1,140,204 (+58.23%) | Filing |
| 2020-06-22 4:52 pm Purchase | 2020-06-15 | 13G | Cardiff Oncology, Inc. CRDF | CAXTON CORP | 1,958,243 9.900% | 1,958,243 (New Position) | Filing |